Literature DB >> 8501256

Ocular ethambutol toxicity: is it reversible?

A Kumar1, S Sandramouli, L Verma, H K Tewari, P K Khosla.   

Abstract

Delayed onset ocular ethambutol toxicity is usually considered to be reversible following prompt withdrawal of the drug. However, in a series of seven consecutive patients with severe visual deficit due to ethambutol toxicity, only 42.2% (3 of the 7 patients) achieved a visual recovery of better than 20/200 after an average follow-up of 8.3 +/- 2.1 months after stoppage of the drug. On fluorescein angiography, three cases (42.2%) progressed to optic atrophy during the follow-up with permanent visual damage. There were no predisposing or risk factors to contribute toward the poor visual gain. In this background, we recommend discontinuation of ethambutol from the antituberculous regimen. As an additional sidelight, the value of visually evoked potential in the monitoring of patients on ethambutol, especially in cases with early periaxial neuritis, has been emphasised.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501256

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  17 in total

1.  Ethambutol induced toxic optic neuropathy in HIV positive patients.

Authors:  Hamzah Mustak; Graeme Rogers; Colin Cook
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  Spectrum and Clinical Course of Visual Field Abnormalities in Ethambutol Toxicity.

Authors:  Thomas Mendel; David Fleischman; R Rand Allingham; Henry Tseng; David A Chesnutt
Journal:  Neuroophthalmology       Date:  2016-04-29

3.  Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy.

Authors:  Samantha J Chai; Rod Foroozan
Journal:  Br J Ophthalmol       Date:  2007-01-10       Impact factor: 4.638

Review 4.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

5.  Multifocal ERG in ethambutol associated visual loss.

Authors:  R S Behbehani; E L Affel; R C Sergott; P J Savino
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

6.  Ethambutol ocular toxicity in a patient with pulmonary tuberculosis - a case report.

Authors:  Ak Tan; Ps Mallika; S Aziz; T Asok; G Intan
Journal:  Malays Fam Physician       Date:  2008-08-31

Review 7.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

8.  Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case.

Authors:  V Scaioli; A Caraceni; C Martini; E Palazzini; E Tarenzi; F Fulfaro; E Munzone
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  Meijun Si; Huiqun Li; Yanru Chen; Hui Peng
Journal:  BMJ Case Rep       Date:  2018-05-18

10.  Ester-prodrugs of ethambutol control its antibacterial activity and provide rapid screening for mycobacterial hydrolase activity.

Authors:  Erik M Larsen; Dominique C Stephens; Nathan H Clarke; R Jeremy Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-08-30       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.